| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8784934 | Advances in Radiation Oncology | 2017 | 21 Pages |
Abstract
Neoadjuvant twice-daily chemoradiation for esophageal cancer is a safe and effective alternative to daily fractionation with low treatment-related mortality and long-term outcomes similar to standard fractionation courses.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Stuart E. MD, PhD, Matthew H. MD, Jae Y. MD, PhD, Jonathan B. MD, James A. MD, Mark B. MD, Susan G. MD, Libin MD, Congying PhD, Feng-Ming MD, PhD, Kyle C. MD,